Testicular lymphoma
diseaseOn this page
Also known as lymphoma of testislymphoma of the testisprimary testicular lymphomaTLYM
Summary
Testicular lymphoma (MONDO:0001472) is a cancer and 45 clinical trials. Top therapeutic interventions include fludarabine phosphate, bendamustine hydrochloride, and alemtuzumab. A subtype of testicular sex cord-stromal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 45
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | testicular lymphoma |
| Mondo ID | MONDO:0001472 |
| DOID | DOID:12253 |
| NCIT | C6810 |
| SNOMED CT | 277664004 |
| UMLS | C0349644 |
| MedGen | 138110 |
| GARD | 0022950 |
| Is cancer (heuristic) | yes |
Also known as: lymphoma of testis · lymphoma of the testis · primary testicular lymphoma · testicular lymphoma · TLYM
Disease family
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › reproductive system neoplasm › sex cord-stromal tumor › testicular sex cord-stromal neoplasm › testicular lymphoma
Related subtypes (9): Sertoli-Leydig cell tumor, testicular gonadoblastoma, testicular Leydig cell tumor, testicular granulosa cell tumor, testicular fibroma, testicular thecoma, testicular sertoli cell tumor, testicular fibrothecoma, testicular sex cord-stromal benign neoplasm
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 45.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 16 |
| PHASE1 | 15 |
| Not specified | 7 |
| PHASE1/PHASE2 | 6 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00006251 | PHASE1/PHASE2 | COMPLETED | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
| NCT00049504 | PHASE2 | COMPLETED | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
| NCT00054639 | PHASE2 | COMPLETED | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
| NCT00072514 | PHASE2 | COMPLETED | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
| NCT00088881 | PHASE2 | TERMINATED | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin’s Lymphoma |
| NCT00089011 | PHASE2 | COMPLETED | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
| NCT00089076 | PHASE1/PHASE2 | TERMINATED | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma |
| NCT00118352 | PHASE2 | COMPLETED | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
| NCT00867529 | PHASE2 | COMPLETED | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
| NCT01177371 | PHASE2 | COMPLETED | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
| NCT01258998 | PHASE2 | COMPLETED | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
| NCT01273766 | PHASE2 | COMPLETED | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
| NCT01326702 | PHASE1/PHASE2 | COMPLETED | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
| NCT01419795 | PHASE2 | TERMINATED | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant |
| NCT01427881 | PHASE2 | COMPLETED | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
| NCT01652014 | PHASE2 | WITHDRAWN | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies |
| NCT01789255 | PHASE2 | COMPLETED | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
| NCT01805037 | PHASE1/PHASE2 | TERMINATED | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
| NCT01839916 | PHASE2 | COMPLETED | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT02213913 | PHASE1/PHASE2 | COMPLETED | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas |
| NCT02281279 | PHASE1/PHASE2 | WITHDRAWN | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT03212807 | PHASE2 | WITHDRAWN | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL |
| NCT01815749 | PHASE1 | ACTIVE_NOT_RECRUITING | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma |
| NCT00458731 | PHASE1 | COMPLETED | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
| NCT00608361 | PHASE1 | COMPLETED | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
| NCT00720135 | PHASE1 | COMPLETED | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
| NCT00890747 | PHASE1 | COMPLETED | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
| NCT01116154 | PHASE1 | TERMINATED | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma |
| NCT01129193 | PHASE1 | COMPLETED | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
| NCT01254578 | PHASE1 | COMPLETED | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
| NCT01567709 | PHASE1 | COMPLETED | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
| NCT01658319 | PHASE1 | COMPLETED | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
| NCT01678443 | PHASE1 | TERMINATED | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
| NCT01748721 | PHASE1 | COMPLETED | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
| NCT01769222 | PHASE1 | TERMINATED | Ipilimumab and Local Radiation for Selected Solid Tumors |
| NCT02109224 | PHASE1 | TERMINATED | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection |
| NCT02168907 | PHASE1 | TERMINATED | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
| NCT01959477 | EARLY_PHASE1 | COMPLETED | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
| NCT00003196 | Not specified | COMPLETED | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
| NCT00014235 | Not specified | COMPLETED | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDARABINE PHOSPHATE | 4 | 9 |
| BENDAMUSTINE HYDROCHLORIDE | 4 | 2 |
| ALEMTUZUMAB | 4 | 1 |
| BRENTUXIMAB VEDOTIN | 4 | 1 |
| DEFERASIROX | 4 | 1 |
| IBRUTINIB | 4 | 1 |
| IPILIMUMAB | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| VELIPARIB | 3 | 2 |
| 6-O-BENZYLGUANINE | 3 | 1 |
| ALISERTIB | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| CPI 613 | 3 | 1 |
| INDIUM IN 111 IBRITUMOMAB TIUXETAN | 3 | 1 |
| OBLIMERSEN SODIUM | 3 | 1 |
| METHOXYAMINE | 2 | 2 |
| AR-42 | 2 | 1 |
| DI-LEU16-IL2 | 1 | 1 |
| CHEMBL4066465 | 0 | 1 |